Abstract
2060
Objectives To assess the clinical impact of 18-F FDG PET/CT on the management of the patients with differentiated thyroid carcinoma who had elevated Tg levels and negative I-131 WBS.
Methods 96 patients with differentiated thyroid carcinoma were included in this study. The findings of PET/CT imaging were compared with histopathology, follow up imaging, or clinical follow-up (including thyroglobulin level) results as a gold standards. The diagnostic accuracy of FDG PET/CT versus I-131 WBS was evaluated for the entire patient group and for those patients with serum thyroglobulin levels of less than 5, 5-10, and more than 10 pmol/L as well as for local recurrences and metastases sites. The impact of FDG PET/CT on therapeutic management has also been evaluated.
Results The sensitivities of 18F-FDG PET/CT at serum thyroglobulin levels between 5-10, and more than 10 pmol/L were 9.7, and 83.4 respectively. PET/CT had an impact on treatment plan in 78 (81.2%) patients: low impact in 42 (53.8 %), moderate in 9 (11.5 %) and high impact in 27(34.6 %) patients. 18F FDG PET/CT identified 24 (75 %) patients with cervical metastases /neck recurrence, 5 (71.4 %) mediastinal, 9 (69.2 %) lung, 6 (75 %) bone and 2 (66.6 %)liver metastases.
Conclusions FDG PET/CT has a high diagnostic accuracy and management impact in patients with suspected residual / recurrent differentiated thyroid carcinoma
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.